Abstract | BACKGROUND: METHODS: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald criteria; 2) who started OFA according to Italian Medicines Agency prescription rules and within 12 months from the RMS diagnosis; 3) naïve to any disease-modifying therapy. The primary outcome was to offer an overview of cellular subsets of RMS naïve patients (time 0) and then after 4 weeks (time 1) and 12 weeks (time 2) on therapy with OFA in a real-world setting. RESULTS: Fifteen patients were enrolled. CD3+ T cell frequencies were higher at time 1 (%80.4, SD 7.7) and time 2 (%82.6, SD 5.8) when compared to time 0 (%72.4, SD 9.8), p = .013. B naïve cells were barely detectable in the OFA group at time 1 (%0.4, SD 0.5) and 2 (%1.4, SD 2.9) when compared to time 0 (%11.5, SD 3.8), p < .001. CONCLUSION: The progressive and increasing use of anti-CD20 drugs imposes the need for larger, prospective, real-world, long-term studies to characterize further immunophenotypes of patients with RMS treated with OFA.
|
Authors | Emanuele D'Amico, Aurora Zanghì, Roberta Fantozzi, Diego Centonze, Carlo Avolio |
Journal | Current neuropharmacology
(Curr Neuropharmacol)
Vol. 21
Issue 12
Pg. 2563-2566
( 2023)
ISSN: 1875-6190 [Electronic] United Arab Emirates |
PMID | 37534789
(Publication Type: Journal Article)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- ofatumumab
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
|
Topics |
- Humans
- Multiple Sclerosis
(drug therapy)
- Prospective Studies
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antibodies, Monoclonal
(adverse effects)
|